News and Trends 26 Nov 2020
AstraZeneca’s Covid-19 Vaccine Proves Its Worth in Phase III
A much anticipated Covid-19 vaccine, developed by the University of Oxford and AstraZeneca, achieved 70% efficacy in phase III interim data. While less effective on paper, it could prove cheaper and easier to distribute than its most advanced competitors. Scientists and politicians heartily received the announcement of promising interim clinical trial results from the Covid-19 […]